Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT

Fig. 3

Patients reporting scores ≥ normative values at baseline and week 12. a Health Assessment Questionnaire-Disability Index (HAQ-DI), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Work Instability Scale for RA (RA-WIS), and Short Form 36 Health Survey (SF-36) PCS and MCS. b SF-36 individual domains. Baseline values and SF-36 domains were re-scored from 0 to 100. ***P < 0.001, **P < 0.01, *P < 0.5 for upadacitinib versus placebo. BL, baseline; BP, Bodily Pain; GH, General Health; MCS, mental component summary; MH, Mental Health; PBO, placebo; PCS, physical component summary; PF, Physical Functioning; RE, Role-Emotional; RP, Role-Physical; SF, Social Functioning; UPA, upadacitinib; VT, Vitality; Wk, week

Back to article page